donepezil has been researched along with Ophthalmoplegia, Progressive Supranuclear in 4 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Donepezil was not effective on cognitive dysfunction and did not change ratings of daily living." | 2.70 | Donepezil in the treatment of progressive supranuclear palsy. ( Barbanti, P; Bonifati, V; Colosimo, C; Fabbrini, G; Gasparini, M; Meco, G; Vanacore, N, 2001) |
| "Donepezil and placebo were administered for 6 weeks each with a 1-month washout period." | 2.70 | Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. ( Grafman, J; Hallett, M; Litvan, I; Pharr, VL; Phipps, M; Salazar, A, 2001) |
| "Success in treating patients with progressive supranuclear palsy and corticobasal degeneration remains exceedingly low." | 1.33 | Treatment of progressive supranuclear palsy and corticobasal degeneration. ( Lang, AE, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kunitoki, K | 1 |
| Mutoh, T | 1 |
| Arai, H | 1 |
| Taki, Y | 1 |
| Lang, AE | 1 |
| Fabbrini, G | 1 |
| Barbanti, P | 1 |
| Bonifati, V | 1 |
| Colosimo, C | 1 |
| Gasparini, M | 1 |
| Vanacore, N | 1 |
| Meco, G | 1 |
| Litvan, I | 1 |
| Phipps, M | 1 |
| Pharr, VL | 1 |
| Hallett, M | 1 |
| Grafman, J | 1 |
| Salazar, A | 1 |
2 trials available for donepezil and Ophthalmoplegia, Progressive Supranuclear
| Article | Year |
|---|---|
Donepezil in the treatment of progressive supranuclear palsy.
Topics: Aged; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Humans; Indans; Male; Middl | 2001 |
Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy.
Topics: Aged; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Female; Humans; Indans; Male; Neuro | 2001 |
2 other studies available for donepezil and Ophthalmoplegia, Progressive Supranuclear
| Article | Year |
|---|---|
Adverse motor effects of progressive supranuclear palsy with frontal lobe signs: A case report.
Topics: Donepezil; Female; Frontal Lobe; Humans; Levodopa; Middle Aged; Single Photon Emission Computed Tomo | 2019 |
Treatment of progressive supranuclear palsy and corticobasal degeneration.
Topics: Amantadine; Cerebral Cortex; Cholinesterase Inhibitors; Corpus Striatum; Donepezil; Dopamine Agents; | 2005 |